Tasonermin
Approved · EMAAlso known as Tumor necrosis factor alfa-1a, Tumour necrosis factor alfa-1a, tasonermin (tumor necrosis fctr alfa-1a), Tasonermina+1 more
Tumor necrosis factor alfa-1a, Tumour necrosis factor alfa-1a, tasonermin (tumor necrosis fctr alfa-1a), Tasonermina, Tumor necrosis factor, soluble form, nonglycosylated.
Recent clinical, regulatory, research and industry developments relating to this drug.
Profile
Canonical identifiers, marketed brand names and mechanism, resolved across RxNorm, ChEMBL and ATC.
Regulatory timeline
The complete regulatory record, grouped by authority — approvals, safety advisories and label changes. Each authority shows its most recent events; expand one to read its full history.
Indication: Beromun is indicated in adults as an adjunct to surgery for subsequent removal of the tumour so as to prevent or delay amputation, or in the palliative situation, for irresectable… Show full indicationShow less
Beromun is indicated in adults as an adjunct to surgery for subsequent removal of the tumour so as to prevent or delay amputation, or in the palliative situation, for irresectable soft-tissue sarcoma of the limbs, used in combination with melphalan via mild hyperthermic isolated-limb perfusion (ILP).
Contains information from the European Medicines Agency (European Medicines Agency), © EMA, reused under CC BY 4.0.
- RxNorm (U.S. National Library of Medicine) — drug identity
- Regulatory event sources are credited in the Regulatory Timeline above.